“And I'd say the currency headwinds are very much kind of in play here for next year, right?”

In context

“y shifting to next year. Just with so many moving pieces, both in revenues and down the P&L with currency and inflation and COVID testing assumptions and so on. So I was hoping sometimes at this point in the year, you might give us some early thoughts on next year. Anything you can provide to help us narrow the range of outcomes would be great. Robert Ford: Sure. I mean, with all those topics, we could spend the whole call on it, right? So I'll provide as broad framework that I can give you here. Obviously, the macro conditions are going to remain challenging, right, Robbie. I don't think that anybody right now as we're planning going into next year, is forecasting that this is just going to ease up, right? So specifically, I would say probably inflation, I don't expect to get better. And I'd say the currency headwinds are very much kind of in play here for next year, right? Those are probably 2 of the big kind of macro kind of impacts for us. But I still see a lot of opportunity for growth as I have been talking about our business and our portfolio. There's a clear path in my mind here for top line growth of high single digits. And you can get there with a variety of looking at across our businesses. So in Medical Devices, we've got a lot of upcoming launches and products that we have launched. So Libre 3, Amulet, Aveir, CardioMEMS, Navitor, we expect to be launching next year here in the U.S. EnSite X, our mapping system, launching a new ablation catheter into the market globally next year also. I'm probably sure there's more that I could kind of rattle off here in terms of devices. So I think the device portfolio looks very strong as we go into next”